Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 6/20 | 0.67 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.52 |
| ▸ | HRH1 | P35367 | 5/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428203 | 0.93 | NPSR1 (0.58) | HTR3ACYP2D6HRH1KCNH2CHRM1 | |
| SCHEMBL7168715 | 0.89 | HTR3A (0.81) | HTR3ACYP2D6HRH1KCNH2CHRM1 | |
| SCHEMBL10967129 | 0.83 | HTR3A (0.71) | HTR3A | |
| SCHEMBL7341277 | 0.82 | HTR3A (0.75) | HTR3ACYP2D6HRH1KCNH2CHRM1 | |
| Lerisetron SCHEMBL141124 | 0.80 | HTR3A (1.00) | HTR3A | |
| Lerisetron SCHEMBL30669539 | 0.80 | HTR3A (1.00) | HTR3A | |
| SCHEMBL4428154 | 0.80 | HSD11B1 (0.58) | P2RX7CYP2D6HRH1KCNH2CHRM1 | |
| Lerisetron SCHEMBL29040939 | 0.79 | HTR3A (0.97) | HTR3A | |
| SCHEMBL3886902 | 0.79 | HTR3A (0.59) | HTR3AALDH1A1SMN1; SMN2 | |
| SCHEMBL15963055 | 0.79 | HTR3A (0.65) | HTR3ACYP2D6HRH1KCNH2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5256665-A | Process for preparing new 2-piperazinylbenzimidazole | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (ES) | 1993-10-26 | — | — | US | claimed |
| EP-0512939-A1 | New 2-piperazinylbenzimidazole derivatives | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1992-11-11 | — | — | EP | claimed |
| US-20090239880-A1 | COMBINATIONS OF MONOAMINE REUPTAKE INHIBITORS AND POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2009-09-24 | — | — | US | disclosed |
| EP-2043641-A2 | COMBINATIONS OF MONOAMINE REUPTAKE INHIBITORS AND POTASSIUM CHANNEL ACTIVATORS | NeuroSearch A/S (DK) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008003667-A2 | COMBINATIONS OF MONOAMINE REUPTAKE INHIBITORS AND POTASSIUM CHANNEL ACTIVATORS | NEUROSEARCH A/S (DK) | 2008-01-10 | — | — | WO | disclosed |
| EP-0512939-B1 | 2-piperazinylbenzimidazole derivatives | ESPANOLA PROD QUIMICOS (ES) | 1999-08-25 | — | — | EP | disclosed |
| US-5256665-A | Process for preparing new 2-piperazinylbenzimidazole | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (ES) | 1993-10-26 | — | — | US | disclosed |
| EP-0512939-A1 | New 2-piperazinylbenzimidazole derivatives | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239880-A1 | COMBINATIONS OF MONOAMINE REUPTAKE INHIBITORS AND POTASSIUM CHANNEL ACTIVATORS | SLC6A2, SLC18A2, SLC6A4 | HTR3A 81/4885P2RX7 367/4885CYP2D6 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.